B7H3 Is An Up-and-coming ImmunotherapyTarget
Several studies have investigated the use of B7H3-targeted immunotherapy drugs in prostate cancer. For example, a phase 1 clinical trial tested an anti-B7H3 antibody called 8H9 in patients with advanced prostate cancer and found that the drug was well-tolerated and showed some evidence of clinical activity.
Another clinical trial tested an anti-B7H3 antibody called enoblituzumab in patients with localized prostate cancer who were not eligible for surgery or radiation therapy. The trial found that enoblituzumab was well-tolerated by patients and showed promising efficacy in shrinking tumors and delaying disease progression.
In addition to antibodies, other types of immunotherapy drugs targeting B7H3 are also being investigated for the treatment of prostate cancer. For example, a phase 1 clinical trial tested a B7H3-targeted CAR T cell therapy in patients with advanced prostate cancer. The treatment was safe and showed some evidence of clinical activity.
While the results of these studies are promising, more research is needed to fully understand the potential of B7H3 as a target for prostate cancer immunotherapy and to determine the optimal use of B7H3-targeted drugs in combination with other therapies.